Benzonatate is a prescription cough suppressant sold under names such as Tessalon. People who are starting a new job, entering a treatment program, or facing a random workplace screen often want to know whether this medication will cause a problem on a drug test. The short answer is that benzonatate is not an opioid, is not a federally controlled substance, and is not one of the substances that any standard 5, 10, or 12 panel immunoassay is designed to detect. That does not mean every cough or cold product is in the clear. Some common ingredients, including dextromethorphan and prescription codeine or hydrocodone cough syrups, interact with drug testing in very different ways, and this page walks through each one plainly.
What Benzonatate Is and How It Works
Benzonatate is chemically related to local anesthetics such as tetracaine rather than to opioid cough suppressants. It works by numbing stretch receptors in the lungs and airways to reduce the cough reflex, not by acting on opioid receptors in the brain the way codeine or hydrocodone do. The current prescribing information, published on the National Library of Medicine's drug label repository, describes benzonatate as a non narcotic antitussive with this local anesthetic mechanism of action, and it does not list any interaction with employer or clinical urine drug screening. You can read the full label at DailyMed.
Is Benzonatate a Controlled Substance?
No. Benzonatate does not appear anywhere on the Drug Enforcement Administration's current alphabetical list of federally controlled substances, which covers every Schedule I through V drug regulated under the Controlled Substances Act. You can check the list directly at the DEA Diversion Control Division's controlled substances index. That same list does include codeine and hydrocodone, both of which are scheduled opioids. That distinction matters for this topic because it explains why a benzonatate prescription does not carry the same drug testing concern that an opioid cough syrup does.
Will Benzonatate Show Up on a Standard Panel?
Workplace and clinical immunoassay panels are built to flag specific drug classes, most commonly amphetamines, cocaine metabolite, marijuana metabolite (THC), opiates, and phencyclidine (PCP) on a basic 5 panel, with benzodiazepines, barbiturates, methadone, and additional opioids added on expanded 10 or 12 panel configurations. Each class has its own antibody based immunoassay that reacts to a defined chemical structure. Benzonatate's structure does not resemble any of those target classes, and no published literature in the National Library of Medicine's PubMed Central database or on FDA drug safety pages reports benzonatate cross reacting with an opiate, amphetamine, PCP, or benzodiazepine immunoassay. In plain terms, there is no credible published cross reactivity evidence connecting benzonatate to a false positive on any standard panel.
Where Cough and Cold Medicine Actually Gets Complicated
Benzonatate is simple, but it sits in a medicine cabinet category that is not. The table below separates the common cough and cold ingredients that have a documented testing interaction from the ones that do not.
| Ingredient or product | Drug class or scheduling | Effect on a standard panel |
|---|---|---|
| Benzonatate (Tessalon) | Non opioid local anesthetic class antitussive, not federally controlled | No published cross reactivity with any standard immunoassay class |
| Dextromethorphan (found in many OTC cough syrups) | Not federally controlled, structurally related to opioids but without opioid receptor activity at normal doses | Reported in published case reports and reviews to cause false positive PCP results, and in some assay formats false positive opiate results, on immunoassay screens |
| Codeine cough syrup (often combined with promethazine) | Schedule V or higher opioid depending on formulation | Expected to trigger the opiate immunoassay class; a true positive, not a false one |
| Hydrocodone cough syrup | Schedule II opioid | Expected to trigger the opiate or expanded opioid immunoassay class; a true positive |
| Diphenhydramine (common antihistamine in nighttime cold formulas) | Not federally controlled | No standard panel target; isolated interference reports exist for some older assay chemistries but it is not part of a routine employer panel |
The dextromethorphan row is the one donors most often confuse with benzonatate because both are marketed as cough suppressants. They are chemically unrelated. A peer reviewed analysis published in the American Family Physician literature and archived on PubMed Central specifically examined how often common over the counter medications, including dextromethorphan, produce a false positive phencyclidine screen, and found dextromethorphan among the medications with documented interference in some immunoassay formats. You can read that analysis at PubMed Central. Benzonatate was not among the medications flagged in that review or in the broader cross reactivity literature.
Screening Immunoassay vs GC/MS or LC/MS Confirmation
Every initial urine or oral fluid cup, dip card, or lab immunoassay result that reads positive is a presumptive result, not a final one. Immunoassays work by detecting a chemical shape, and a handful of unrelated compounds can occasionally bind closely enough to cause a nonnegative screen even when the targeted drug is absent. That is why any presumptive positive on a regulated or employer program is sent to a certified laboratory for gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS) confirmation. These confirmation methods identify the exact molecule present, down to its specific structure, and they are what separates a true positive for an opioid like hydrocodone from an unrelated compound that merely triggered the screening antibody. Because benzonatate has no documented cross reactivity to begin with, it would not be expected to produce a nonnegative screen in the first place, but confirmation testing exists precisely to resolve cases where any medication is in question.
The MRO Review and Prescription Documentation
For any DOT regulated or similarly structured testing program, a nonnegative laboratory result does not go straight to the employer. It goes first to a Medical Review Officer (MRO), a licensed physician trained to review laboratory results and contact the donor confidentially about any legitimate medical explanation, including a current prescription. The process, documentation standards, and the donor's right to explain a result before it is reported as verified positive are set out in the federal procedures at 49 CFR Part 40, Subpart G. A person taking benzonatate, or any other prescribed cough medicine, should keep the prescription label or a pharmacy printout available and be ready to provide it to the MRO or testing administrator if asked. This is the correct channel for resolving any legitimate medication question, not an assumption that a result will or will not be flagged.
What Employers and Testing Programs Should Do
Employers do not need to treat benzonatate as a testing risk, since it is not part of any standard panel's target class and has no published cross reactivity record. The more useful step is making sure collection staff and donors understand the difference between an OTC dextromethorphan product and a prescription opioid cough syrup, since those two categories behave very differently on a screen. Programs that run a standard 5, 10, or 12 panel configuration can review how each panel is built and which classes it targets using the detailed breakdowns in our guides to 5 panel vs 10 panel vs 12 panel drug tests, and donors who want the specific science behind the dextromethorphan and PCP interaction can read our dedicated breakdown of how NyQuil and other dextromethorphan products can affect a PCP screen. For programs that need cup, dip card, or oral fluid devices for a documented, lab backed testing program, the current panel options are listed at our drug test cup collection.
Frequently asked questions
Does benzonatate show up as an opiate on a drug test?
No. Benzonatate is not an opioid and is not a federally controlled substance, so it is not targeted by the opiate immunoassay class used on standard panels.
Is benzonatate the same as dextromethorphan?
No. They are both marketed as cough suppressants but they are chemically unrelated. Dextromethorphan has published reports of causing false positive PCP or opiate immunoassay results in some assay formats, while benzonatate has no such published cross reactivity record.
Will a prescription for benzonatate cause a failed drug test?
There is no published evidence that benzonatate causes a false positive on any standard immunoassay class. If a result is ever questioned, the donor's prescription documentation can be reviewed through the Medical Review Officer process.
Do codeine or hydrocodone cough syrups show up on a drug test?
Yes. These are scheduled opioid medications and are expected to trigger the opiate or expanded opioid immunoassay class as a true positive, which is different from the false positive interference reported for dextromethorphan.
What should someone do if they are taking benzonatate before a scheduled drug test?
Bring the prescription bottle or a pharmacy printout to the collection site and be prepared to discuss any current medication with the Medical Review Officer if contacted. This is a documentation step, not a medical decision, and donors should not stop or adjust any prescribed medication without talking to the prescribing clinician.
Does a positive screen always mean a drug was present?
No. An immunoassay screen is presumptive. Any nonnegative result on a regulated program is sent for GC/MS or LC/MS laboratory confirmation before it is reported as a verified result.
This article is general information about drug test screening and confirmation science. It is not medical or legal advice. Anyone with questions about a specific medication or test result should talk to a licensed clinician, the Medical Review Officer assigned to their program, or qualified legal counsel.
